Royalty Report: Medical, Fertility / non-Fertility, Drugs – Collection: 245926

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Medical
  • Fertility / non-Fertility
  • Drugs
  • Therapeutic
  • cell therapy

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 249075

License Grant
Licensor hereby grants to Licensee an exclusive royalty-bearing right and license in the Licensee Field throughout the Territory, with the right to grant sublicenses in accordance with the terms of this Agreement, under Licensors interest in the Licensor Development Technology and the Joint Development Technology to research, develop, have developed, use, manufacture, have manufactured, sell, offer for sale and have sold Licensee Products.
License Property
Oocyte cryopreservation, sometimes known as egg freezing, is a method of fertility preservation.

Covered Products shall mean any product or service related to the collection, processing and cryopreservation of human oocytes in any country in the Territory that meets any of the following criteria  (i) the development, manufacture or sale of any such product or any process undertaken in the provision of such services is covered by a Valid Claim of any Patent in such country included in the Hospital Patent Rights or any Patent in such country covering any portion of the Licensee Development Technology or Joint Development Technology (a Patented Covered Product); (ii) the development, manufacture or sale of any such product or any process undertaken in the provision of such services has, at any time, been covered by a Valid Claim of any Patent in such country included in the Hospital Patent Rights or any Patent in such country covering any portion of the Licensee Development Technology or Joint Development Technology, and all such Valid Claims have expired or been invalidated (an Expired Covered Product); or (iii) such product or service (a) is not described in clauses (i) or (ii) above and (b) is developed, manufactured, sold or provided using Licensee Development Technology or Joint Development Technology that is not described in or dominated by a Valid Claim of any Patent included in the Hospital Patent Rights or any Patent covering any portion of the Licensee Development Technology or Joint Development Technology (a  Development Technology Covered Product).

U.S. patent application serial number 09/798,327, filed March 12, 2001, entitled 'Microinjection of Cryoprotectants for Preservation of Oocytes.'
U.S. patent application serial number 09/859,105, filed May 16, 2001, entitled 'Microinjection of Cryoprotectants for Preservation of Oocytes'

Field of Use
Field shall mean the field of human oocyte cryopreservation.  Licensee Field shall mean the field of cryopreservation of mammalian cells other than human oocytes.  Oocyte cryopreservation, sometimes known as egg freezing, is a method of fertility preservation.

IPSCIO Record ID: 245926

License Grant
Licensor hereby grants Licensee an exclusive royalty-bearing right and sublicense in the Field throughout the Territory, with the right to grant further sublicenses in accordance with the terms of this Agreement, under the Hospital Patent Rights to research, develop, have developed, use, manufacture, have manufactured, sell, offer for sale and have sold Covered Products.

Licensor hereby grants to Licensee an exclusive royalty-bearing right and license in the Field throughout the Territory, with the right to grant sublicenses in accordance with the terms of this Agreement, under Licensors interest in the Licensor Development Technology and the Joint Development Technology to research, develop, have developed, use, manufacture, have manufactured, sell, offer for sale and have sold Covered Products.

License Property
Covered Products shall mean any product or service related to the collection, processing and cryopreservation of human oocytes in any country in the Territory that meets any of the following criteria  (i) the development, manufacture or sale of any such product or any process undertaken in the provision of such services is covered by a Valid Claim of any Patent in such country included in the Hospital Patent Rights or any Patent in such country covering any portion of the Licensor Development Technology or Joint Development Technology (a Patented Covered Product); (ii) the development, manufacture or sale of any such product or any process undertaken in the provision of such services has, at any time, been covered by a Valid Claim of any Patent in such country included in the Hospital Patent Rights or any Patent in such country covering any portion of the Licensor Development Technology or Joint Development Technology, and all such Valid Claims have expired or been invalidated (an Expired Covered Product); or (iii) such product or service (a) is not described in clauses (i) or (ii) above and (b) is developed, manufactured, sold or provided using Licensor Development Technology or Joint Development Technology that is not described in or dominated by a Valid Claim of any Patent included in the Hospital Patent Rights or any Patent covering any portion of the Licensor Development Technology or Joint Development Technology (a  Development Technology Covered Product).

Licensor Product shall mean any service or product related to the collection, processing and cryopreservation of mammalian cells other than human oocytes in any country in the Territory for which the development, manufacture or sale of any such product or any process undertaken in the provision of such services is covered by a Valid Claim of any Patent covering Licensee Development Technology or Joint Development Technology.

U.S. patent application serial number 09/798,327, filed March 12, 2001, entitled 'Microinjection of Cryoprotectants for Preservation of Oocytes.'

U.S. patent application serial number 09/859,105, filed May 16, 2001, entitled 'Microinjection of Cryoprotectants for Preservation of Oocytes'

Field of Use
Field shall mean the field of human oocyte cryopreservation.  Licensor Field shall mean the field of cryopreservation of mammalian cells other than human oocytes.

Technology relates to cryopreserve and store unfertilized human eggs.

IPSCIO Record ID: 203352

License Grant
Licensor grants an exclusive license under the Licensed Technology to research, develop, make, have made, import, have imported, use, have used, sell, have sold, offer for sale, have offered for sale, and otherwise exploit Licensed Products and Licensed Media throughout the Territory.
License Property
The Licensed Media means cryopreservation media covered by, or made by a process covered by, a Valid Claim included in the Licensed Patent Rights, or which utilizes the Technology or Improvements in material part.

The Licensed Product means any product, device, service or system in the Field which is covered by, or is made by a process covered by, a Valid Claim included in the Licensed Patent Rights, or which utilizes the Technology or Improvements in material part, but excluding Licensed Media.

The Licensed Technology means the Licensed Patent Rights, the Technology and the Improvements.  The patent is for Cryopreservation and cell culture medium comprising less than 50 mM sodium ions and greater than 100 mM chlorine salt.

The Materials means the CJ panel of media, the CJ3 Freezing Medium and the CJ2 Thawing Medium.

Oocyte cryopreservation include using our product candidate to aid women (or couples) who require IVF, but who have ethical concerns about embryo cryopreservation and those individuals seeking donor oocytes, but for whom the logistics of coordinating a donor-recipient cycle present a challenge. We do not intend to use our oocyte product in connection with the use or harvesting of stem cells from embryos.

Field of Use
The field is human oocyte and human embryo cryopreservation with reference to use of the Materials, or any Improvements to the Materials.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.